



164

# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
[WWW.FULBRIGHT.COM](http://WWW.FULBRIGHT.COM)

STEVEN L. HIGHLANDER  
PARTNER  
[SHIGHLANDER@FULBRIGHT.COM](mailto:SHIGHLANDER@FULBRIGHT.COM)

DIRECT DIAL: (512) 536-3184  
TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

April 21, 2003

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: BOX DD Commissioner for Patents, Washington, DC 20231, on the date below:	
April 21, 2003	Date
_____ Steven L. Highlander	

BOX DD  
Commissioner for Patents  
Washington, DC 20231

TECH CENTER 1600/2900

APR 25 2003

RE: *U.S. Patent Application No. 10/043,877 entitled "ANTIHelmintic DRUGS AS A TREATMENT FOR HYPERPROLIFERATIVE DISEASES" – Tapas Mukhopadhyay et al.*  
*Our reference: INRP:095US*  
*Client reference: MDA99-067*

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references A9-A14.

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/INRP:095US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,  
\_\_\_\_\_  
Steven L. Highlander  
Reg. No. 37,642

SLH/cmb  
Encl.: as noted  
25284729.1